357 TEHAMA STREET, FLOOR 3, SAN FRANCISCO, CA
Financial Results, Press Release
Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan, Investor Presentation
Investor Presentation
Reports Third Quarter 2025 Financial Results and Provides Business Update
Shareholder votes
FY 2025
Q3
Q2
Q1
FY 2024
Registration Statement for Securities to be Offered to Employees
S-3ASR
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRER14A
PRE 14A
Statement of Changes in Beneficial Ownership
Definitive Revised Proxy Statement
Correspondence
Submission Upload